Loading
Cellogen Therapeutics
A Delhi start-up developing bispecific CD19 and CD20 CAR-T cells and gene therapies for thalassaemia, aiming to cut treatment costs by up to 90%; still before its first trial.
Overview
Cellogen Therapeutics is a New Delhi company developing bispecific, third- and fourth-generation CAR-T cells that target CD19 and CD20 at the same time to reduce antigen-loss relapse, plus genetic therapies for beta-thalassaemia and sickle cell disease. In its public statements it reports promising laboratory results and plans to begin clinical trials; it has no approved products. It is one of a growing group of Indian cell therapy start-ups following ImmunoACT and Immuneel, and its stated aim is to reduce treatment costs by up to 90% with indigenous products.
Similar pages
- CompanyImugene
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma.
- TrialStudy of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Shares CD20, CD19, Diffuse large B-cell lymphoma.
- PersonJae H. Park
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
- CompanyLEAH Labs
Shares CD20, CAR-T cell therapy, Diffuse large B-cell lymphoma.
- CompanyPoseida Therapeutics
Shares CD20, CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma.
- IdeaPlan the second CAR-T target before the first one is lost
Shares CD20, Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy.
- PersonChristopher R. Flowers
Shares CD20, CD19, Diffuse large B-cell lymphoma.
- IdeaCollect and freeze T cells at diagnosis for high-risk patients, before chemotherapy
Shares Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy, Diffuse large B-cell lymphoma.